| Biomarker ID | 32 |
| PMID | 12441933 |
| Year | 2002 |
| Biomarker | Triiodothyronine |
| Biomarker Basis | Concentration Based (ng/dl) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in Prostate Cancer (Control: 72 ±24.9; PCa: 83.9 ±18.1) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Normal Prostate vs Localised Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | 208 samples were taken. 161 with localized prostate cancer, 20 with BPH (Benign Prostatic Hyperplasia ) and 27 controls. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p = 0.048 |
| Method Used | Fluorometric Immunoassay |
| Clinical | No |
| Remarks | Triiodothyronine was checked for both patients with Prostate cancer and BPH, and it was found higher for patients with BPH. Though it was found higher than controls in both BPH and Prostate cancer |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | Triiodothyronine |